Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco Ii)
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Acronyms PASCO II
- Sponsors Hospira; Pfizer
- 16 Jun 2017 Planned number of patients changed from 4500 to 6700.
- 25 Apr 2017 Planned End Date changed from 30 Mar 2020 to 1 Apr 2022.
- 25 Apr 2017 Planned primary completion date changed from 31 Jul 2018 to 1 Apr 2022.